Survey: Half Of Companies Throw Big Bucks At FDA-483 Observations, While Heads Roll At A Quarter Of Firms After Poor Inspection Results
This article was originally published in The Gray Sheet
Executive Summary
A survey of 310 industry stakeholders found that extra resources are given to functional areas singled out by agency investigators for noncompliance at 49% of device firms, but respondents also said additional assets don't always equate to improved device quality. "The challenge for us in the quality area is to ensure that we understand what the appropriate amount of staffing is once we reach development of the processes that we need, and what we need as far as resources to maintain those processes," Meridian Bioscience's Susan Rolih says. Meanwhile, 24% of survey-takers say employees are fired or penalized when there are poor inspection outcomes – a knee-jerk reaction that experts say can negatively affect worker morale. Also: An overwhelming majority of survey respondents, 68%, say investigators should list observations on an FDA-483 from major to minor; 66% say they address the riskiest FDA observations first; 93% tackle so-called "discussion items"; and more.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.